Allergan to Acquire earFold(TM), an Innovative Medical Device for the Correction of Prominent Ears (y 2)

Publicado 04/11/2015 11:02:12CET

earFold(TM) is an implant made of a short strip of nitinol metal alloy, which is specifically designed to retain a preset shape. Nitinol alloy is widely used in medicine and is the same material that is used for coronary artery stents (for patients with heart disease due to a blockage of their arteries). The implant consists of a curved, wafer-thin strip of metal (approximately the same thickness as a human hair) which is plated with 24-carat gold to reduce the visibility of the implant under the skin. earFold(TM) implants reshape the ears with a simple procedure lasting just a few minutes.[1]

About Northwood Medical Innovation Ltd 

Northwood Medical Innovation Ltd (NMI) was incorporated in 2010 to provide a vehicle for investment in the earFold(TM) concept.  NMI is a privately held company based in London and was founded by the inventor of earFold(TM) - Dr Norbert V Kang - a Plastic Surgeon working at the Royal Free Hospital in London.

Marie-Claire Haines has been the Managing Director of the company since 2010. During this time NMI has successfully managed the early prototyping and development of the earFold(TM) concept, taking the technology through cadaveric and finally human clinical trials. The earFold(TM) implant has been commercialised in the UK since 2013, and was recently awarded a CE mark in April 2015, enabling NMI to start expanding sales in Europe and other countries.

About Allergan 

Allergan plc , headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model - Growth Pharma.  Allergan is focused on developing, manufacturing and commercialising innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.

Allergan markets a portfolio of high quality products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.

Allergan Forward-Looking Statement  

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Quarterly Report on Form 10-Q for the quarter ended March 31, 2015 (such periodic public filings having been filed under the "Actavis plc" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.


1) earFold Instructions For Use. 2014

2) Patient Info. Prominent Ear: Last

accessed July 2015

3) Last accessed Sept 2015

4) NHS NHS. Ear reshaping: Last accessed

October 2015.  

5) ISAPS International Survey on Aesthetic/Cosmetic. Procedures Performed in 2014

6) Allergan data on file 0077

7) Allergan data on file 0080

CONTACT: Janet Kettels +44-7738-506-476Karen Dennehy +44-7824-017-950Lisa DeFrancescoInvestor Relations +1-862-261-7152

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación